The first 60 days: Gallbladder cancer
Gallbladder cancer is a cancer of the bile-storing sac under the liver, most often found by chance when the gallbladder is removed for stones. Caught early, a second operation to clear the liver bed and nodes can cure it; for advanced disease, chemotherapy now comes with an immunotherapy partner, and HER2-directed antibodies help the subset whose tumours over-express HER2. Below, week by week, is what OnCo's record of Gallbladder cancer says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Unresectable or metastatic, first line, Second line and biomarker-directed.
- SurgeonNamed in the standard of care for: Incidental cancer at cholecystectomy, T1b or deeper.
- Medical oncologistNamed in the standard of care for: After resection, Unresectable or metastatic, first line, Second line and biomarker-directed.
- Clinical oncologist (radiotherapy)Named in the standard of care for: After resection.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
- 1.Unresectable or metastatic, first lineNCCN category Category 1 (durvalumab or pembrolizumab with gemcitabine-cisplatin), NCCN Guidelines: Biliary Tract Cancers
Gemcitabine-cisplatin plus durvalumab (TOPAZ-1) or pembrolizumab (KEYNOTE-966), with molecular profiling at diagnosis.
- 2.Incidental cancer at cholecystectomy, T1b or deeperNCCN category Category 2A, NCCN Guidelines: Biliary Tract Cancers
Re-resection: liver bed (segments IVb/V) with portal lymphadenectomy, and bile duct excision if the cystic duct margin is positive; port sites are no longer routinely excised.
- 3.After resectionNCCN category Category 1 (capecitabine), BILCAP (Lancet Oncol 2019); ASCO adjuvant biliary guideline 2019
Adjuvant capecitabine for six months (BILCAP; ASCO guideline 2019); chemoradiation considered for positive margins or node-positive disease.
FOLFOX (ABC-06); zanidatamab for HER2-positive disease after prior therapy (HERIZON-BTC-01); tumour-agnostic options for MSI-high (pembrolizumab), BRAF V600E (dabrafenib-trametinib) and NTRK fusions (larotrectinib, entrectinib).
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example T stage on cholecystectomy pathology, HER2 IHC/ISH, MSI / mismatch repair, BRAF V600E, NTRK fusions), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Adenocarcinoma, Papillary adenocarcinoma, Adenosquamous and squamous carcinoma.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Incidental cancer at cholecystectomy, T1b or deeper
- For my situation (incidental cancer at cholecystectomy, t1b or deeper), which of the standard options do you recommend and why?Guideline options include: Re-resection: liver bed (segments IVb/V) with portal lymphadenectomy, and bile duct excision if the cystic duct margin is positive; port sites are no longer routinely excised.
After resection
- For my situation (after resection), which of the standard options do you recommend and why?Guideline options include: Adjuvant capecitabine for six months (BILCAP; ASCO guideline 2019); chemoradiation considered for positive margins or node-positive disease.
- How do the results of BILCAP apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Unresectable or metastatic, first line
- For my situation (unresectable or metastatic, first line), which of the standard options do you recommend and why?Guideline options include: Gemcitabine-cisplatin plus durvalumab (TOPAZ-1) or pembrolizumab (KEYNOTE-966), with molecular profiling at diagnosis.
- Am I a candidate for Gemcitabine + cisplatin, Durvalumab, Pembrolizumab, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of TOPAZ-1 and KEYNOTE-966 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Second line and biomarker-directed
- For my situation (second line and biomarker-directed), which of the standard options do you recommend and why?Guideline options include: FOLFOX (ABC-06); zanidatamab for HER2-positive disease after prior therapy (HERIZON-BTC-01); tumour-agnostic options for MSI-high (pembrolizumab), BRAF V600E (dabrafenib-trametinib) and NTRK fusions (larotrectinib, entrectinib).
- Am I a candidate for FOLFOX (5-FU, leucovorin, oxaliplatin), Zanidatamab, Dabrafenib + trametinib or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of Zanidatamab, HERIZON-BTC-302, Trastuzumab deruxtecan, Gemcitabine-cisplatin + PD-(L)1 blockade in biliary cancer?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Most patients present too late for surgery; ultrasound-based surveillance in high-incidence regions and cholecystectomy policies are being evaluated”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Gallbladder cancer is under-represented and rarely analysed separately in biliary trials; HERIZON-BTC-302 and registry efforts are starting to report it as its own disease”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.
- HERIZON-BTC-302Phase 3 · recruiting · NCT06282575First-line HER2-positive advanced biliary tract cancer: zanidatamab + standard of care (GemCis ± PD-1) vs standard of care
- Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersPhase 2 · active · NCT04430738A Phase 1b/2 Dose Escalation and Expansion Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
- Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract CancerPhase 1/2 · recruiting · NCT07641036A Phase 1/2, Open-Label, Biomarker-Selected Study of Allogeneic Dual-Target HER2/CEACAM5 Chimeric Antigen Receptor Natural Killer Cells (EB-HC01) in Participants With Unresectable or Metastatic Cholangiocarcinoma and Other Biliary Tract Cancers
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Gallbladder cancer: the full pageGallbladder cancer is a cancer of the bile-storing sac under the liver, most often found by chance when the gallbladder is removed for stones. Caught early, a second operation to clear the liver bed and nodes can cure it; for advanced disease, chemotherapy now comes with an immunotherapy partner, and HER2-directed antibodies help the subset whose tumours over-express HER2.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Intrahepatic, perihilar, distal and gallbladder cancer: Bile duct cancers are named by where they start: inside the liver, at the hilum where the ducts join, in the lower duct near the pancreas, or in the gallbladder.
- Lymphadenectomy (lymph node dissection): Surgically removing the lymph nodes that drain a tumour, both to stage the cancer and to clear any spread.
- Hepatectomy (liver resection): Cutting out the part of the liver containing tumour.
- CA 19-9: A sugar molecule shed into the blood by most pancreatic cancers; useful to follow treatment, not to screen.
- Obstructive jaundice and biliary obstruction: Yellowing of the skin and eyes because a tumour blocks the bile duct, most often pancreatic or bile duct cancer.
Every term links to the glossary.